InterShunt’s EASE HF2 Early Feasibility Study Begins Enrollment

June 30, 2025—InterShunt Technologies, Inc. announced the commencement of the EASE HF2 early feasibility study (EFS), which is evaluating the company’s device for reducing elevated left atrial pressure and improving symptoms like shortness of breath in patients with heart failure with reduced ejection fraction (HFrEF).

According to InterShunt Technologies, the EASE HF2 study will enroll 20 patients, including patients with HFrEF at up to six sites in the United States.

The first study procedure using the InterShunt device was performed by Sitaramesh Emani, MD, and the structural heart intervention team at The Christ Hospital Health Network in Cincinnati, Ohio.

“We’re excited to get this study started,” commented Dr. Emani in the company’s press release. “The first procedure went smoothly, and the patient went home the next day feeling well. It’s an encouraging start, and we’re hopeful this treatment can help many more people.”

InterShunt stated that the catheter system it is developing securely captures and excises a defined piece of tissue from the interatrial septum, creating a left-to-right atrial shunt that offloads elevated left atrial pressure, reducing symptoms in heart failure patients. The mechanical system does not use implants or energy, noted the company.